Amgen's Dividend Against Revolution Medicines' Cash Burn

A Motley Fool comparison published Sept. 11, 2026 weighs profitable, dividend-paying Amgen against Revolution Medicines, which is burning cash to fund a potential major cancer drug launch; AMGN last traded at 377.35, down 1.34% on the day, while RVMD was at 203.77, up 0.21%.

Two healthcare stocks, two entirely different financial machines. Amgen (AMGN) earns money today and hands a growing slice of it back to shareholders as a dividend. Revolution Medicines (RVMD) earns nothing of the sort; it is spending cash to push a cancer drug toward what could be one of the more consequential oncology launches in years. The question posed by Motley Fool on Sept. 11 — which is the better buy in 2026 — is really a question about which risk an investor is being paid to take.

The tape that day did not settle it. As of the last trade at 20:00 GMT on Friday, Sept. 11, 2026, Amgen was quoted at 377.35, down 1.34% from a prior close of 382.47, with a session range of 377.22 to 386.99. Revolution Medicines was at 203.77, up 0.21% from 203.35, having swung between 197.81 and 206.36. Both moved against a firmly positive backdrop: SPY, the S&P 500 tracker, rose 0.85% to $764.29; QQQ added 0.87% to $714.88; and DIA gained 0.97% to $525.79.

An income stock that closed the week below the market

Amgen's appeal, as the comparison frames it, is arithmetic that already exists: profits today, a dividend today, and a dividend that has been rising. That is a different proposition from most of biotech, where the payoff is a future event. Investors in a large, profitable drugmaker are buying an installed base of commercial products and the cash they throw off, then hoping the pipeline and business development can replace revenue as patents run down.

Friday's move went the other way, though. Amgen finished the session at the very bottom of its range — 377.35 against a low of 377.22 — while the three major benchmark funds all closed up around a percentage point. Set the stock's 1.34% decline against SPY's 0.85% gain and the one-day gap is roughly 2.2 percentage points of underperformance, an illustrative spread rather than a reported figure. A single day tells you little about a dividend payer's thesis, but closing on the low in an up market is the shape of a stock being sold rather than merely drifting.

The practical point for income-focused buyers is that dividend growth compounds only if the underlying earnings hold up. That is where the scrutiny belongs with any large-cap pharma name: not on the current yield, but on what replaces the products funding it. Neither the payout ratio nor the dividend growth rate is quantified in the material at hand, so treat those as the questions to take to the company's own filings before sizing a position.

Revolution Medicines is buying time, not earnings

Revolution Medicines sits at the opposite end of the spectrum. It burns cash, deliberately, to fund late-stage development and the build-out that a commercial launch requires — manufacturing, medical affairs, a sales organization — all of which has to be paid for before a single prescription is written. In clinical-stage biotech, the two numbers that matter more than any income statement line are the quarterly burn and the cash runway it implies. Those determine whether a company reaches its catalyst on its own balance sheet or has to sell shares to get there.

The stock's behavior on Friday reflects that binary character. Revolution Medicines traveled from 197.81 to 206.36 intraday — a range of about 8.55 points, roughly 4.2% of the prior close, on our calculation — and ended the day almost exactly where it started, up 0.21%. That is a stock whose price is being argued over in real time, closing flat only because the argument didn't resolve. Amgen's whole session spanned a narrower band.

Investors weighing a name like this should be explicit with themselves about what they are underwriting: not a discounted cash flow, but a probability. The drug either works and reaches the market on a commercially meaningful timeline, or the capital spent getting there is written off. There is very little middle ground, and the equity is priced accordingly.

Dilution risk versus patent risk

The cleanest way to compare the two is by the specific thing that can go wrong with each.

• Amgen: the risk is erosion. Exclusivity expires, competitors arrive, pricing pressure builds, and the earnings funding the dividend shrink faster than the pipeline refills them. The failure mode is slow and visible years in advance.
• Revolution Medicines: the risk is twofold — clinical failure, and the financing needed before commercial revenue arrives. Every equity raise between now and launch dilutes existing holders; every delay extends the period over which cash goes out with none coming back. The failure mode is abrupt.
• Both: policy and pricing risk applies across the sector regardless of profitability, and neither company controls it.

An investor's honest answer usually depends on what the rest of the portfolio already holds. If the book is heavy in speculative growth, a profitable dividend payer is the diversifier. If it is entirely income and index funds, a single-catalyst biotech is the position that changes the return distribution — and it is the one that should be sized small enough to be wrong about.

What to watch from here

For Revolution Medicines, the calendar is the thesis. Data readouts, regulatory filing and decision dates, and any announced financing are the events that reprice the stock, and each one arrives on a date the company discloses. Between those dates, the share price mostly reflects sentiment about the sector, which is why a 4%-plus intraday swing can end in a 0.21% close.

For Amgen, the checkpoints are quarterly: revenue by product, the trajectory of the dividend declaration, and management's commentary on what is coming off patent and what is coming through the pipeline. A day like Friday — a decline into a rising market — matters only if it becomes a pattern tied to one of those disclosures.

Neither stock is a substitute for the other, and the "better buy" framing obscures that. One is being bought for the cash it produces now; the other for the cash it might produce later. The only genuinely wrong answer is owning the second while expecting the first one's behavior.

Key facts

• AMGN last price: 377.35, -1.34%, as of 20:00 GMT Sept. 11, 2026
• RVMD last price: 203.77, +0.21%, as of 20:00 GMT Sept. 11, 2026
• Market backdrop: SPY $764.29 (+0.85%), QQQ $714.88 (+0.87%), DIA $525.79 (+0.97%)
• Core contrast: Amgen profitable with a growing dividend; Revolution Medicines burning cash pre-launch

Frequently asked questions

How did Amgen and Revolution Medicines trade on Sept. 11, 2026?

As of the last trade at 20:00 GMT on Friday, Sept. 11, 2026, Amgen was quoted at 377.35, down 1.34% from a prior close of 382.47, with a day range of 377.22 to 386.99. Revolution Medicines traded at 203.77, up 0.21% from 203.35, after ranging between 197.81 and 206.36 during the session.

What is the basic difference between the two companies?

Amgen is profitable and pays a dividend that has been growing, meaning shareholders receive cash from earnings the company generates today. Revolution Medicines is burning cash to fund development and preparation for what could be one of the most important cancer drug launches in years, so its value rests on a future clinical and commercial outcome rather than current profits.

Why does cash burn matter so much for a clinical-stage biotech?

A company with no product revenue funds itself from cash on hand. The quarterly burn rate and the runway it implies determine whether the company can reach its key clinical or regulatory milestone without raising more money. If it has to raise equity first, existing shareholders are diluted, which reduces their share of any eventual success.

Did both stocks underperform the market that day?

Relative to the benchmarks, yes. SPY rose 0.85%, QQQ 0.87% and DIA 0.97% on the day. Amgen fell 1.34% and closed at 377.35, essentially at its session low of 377.22. Revolution Medicines rose 0.21%, a gain, but smaller than any of the three major benchmark funds posted.

What should an investor watch next for Revolution Medicines?

The company's own disclosed calendar: clinical trial data readouts, regulatory submission and decision dates, and any announcement of new financing. Those events are what reprice a pre-revenue biotech. Between them, the share price tends to track broader sector sentiment, which explains large intraday swings that end in nearly flat closes.

Is a dividend-paying pharma stock automatically the safer choice?

It is a different risk, not an absent one. A profitable drugmaker's dividend depends on earnings holding up as products lose exclusivity and face competition or pricing pressure. That erosion is usually slow and visible in advance, unlike a binary trial outcome, but it can still reduce the earnings that fund a growing payout.

Sources

• Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? — Motley Fool

Photo: cottonbro studio · Pexels Licence — source